UAE Pharmaceutical Market Growth, Size, and Forecast Report 2026-2034
IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the UAE pharmaceutical market. The UAE pharmaceutical market size increased from USD 4.45 Billion in 2025 to USD 4.99 Billion in 2026 and is projected to reach USD 8.59 Billion by 2034, growing at a compound annual growth rate of 7.01% from 2026 to 2034. This growth is primarily driven by the escalating prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, substantial government investments in healthcare infrastructure and local drug manufacturing, proactive regulatory reforms that accelerate access to innovative therapies and biosimilars, and the country's expanding role as a medical tourism and regional pharmaceutical distribution hub.
The UAE pharmaceutical sector is moving from a predominantly import-dependent, distribution-led model toward an innovation-driven manufacturing and research ecosystem aligned with the country's Vision 2031 framework. A growing population and one of the highest adult diabetes prevalence rates globally are sustaining long-term demand for chronic disease therapies, while national screening programs are converting previously undiagnosed patients into actively treated populations. Federal regulation has been consolidated under the Emirates Drug Establishment, which is shortening approval timelines and positioning the UAE among the first countries worldwide to authorize several new medicines. At the same time, Abu Dhabi and Dubai are building life sciences clusters that combine genomics, AI, clinical trials, and advanced manufacturing. Together, these forces support steady growth across both conventional pharmaceuticals and biologics through the forecast period, strengthening the overall pharmaceutical industry UAE.
UAE Pharmaceutical Market at a Glance:
Market Size (2025): USD 4.45 Billion
Market Size (2026): USD 4.99 Billion
Projected Market Size (2034): USD 8.59 Billion
CAGR (2026-2034): 7.01%
Leading Type: Pharmaceutical Drugs, with a 71.6% share in 2025
Leading Nature: Conventional, with an 88.4% share in 2025
Largest Region: Dubai, with a 39.7% share in 2025
How AI is Reshaping the Future of the UAE Pharmaceutical Market
AI-Enabled Drug Discovery Built on Genomic Data: In April 2025, Abu Dhabi health group M42 made a strategic investment in Juvenescence and formed a partnership to identify and develop a pipeline of AI-enabled therapeutics for age-related and life-threatening diseases. The collaboration combines Juvenescence's AI-enabled discovery technology with M42's genomics, biobanking, and clinical trial infrastructure, including the Abu Dhabi Biobank, which has stored over 900,000 samples.
AI-Powered Vaccine Research and Manufacturing: In June 2026, the Department of Health Abu Dhabi signed an MoU with Sanofi at the BIO International Convention to explore a Vaccine Innovation Centre in Abu Dhabi focused on AI-enabled vaccine design, mRNA technologies, clinical development, and clinical manufacturing. The centre is planned within Abu Dhabi's HELM (Health, Endurance, Longevity and Medicine) cluster, which brings research, regulation, and manufacturing into a single ecosystem.
AI in Chronic Disease Care and Clinical Research: In October 2026, M42, Oracle, and AstraZeneca announced a collaboration to advance AI-enabled hypertension care and clinical research in Abu Dhabi, building on AstraZeneca and Oracle's global partnership to explore locally relevant applications. Such initiatives target the chronic conditions that generate the bulk of UAE pharmaceutical demand, linking AI-driven diagnosis and patient management directly to treatment uptake.
Grab a sample PDF of this report: https://www.imarcgroup.com/uae-pharmaceutical-market/requestsample
UAE Pharmaceutical Market Trends and Drivers:
The core demand driver for the UAE pharmaceutical market is the sharp and sustained rise in chronic disease prevalence, attributable to rapid urbanization, sedentary lifestyles, dietary habits, and demographic growth. Conditions including type 2 diabetes, cardiovascular disease, hypertension, obesity, and various cancers now account for the majority of the national disease burden, and the International Diabetes Federation has identified the UAE as having one of the highest adult diabetes prevalence rates globally. Government-initiated national screening programs are improving diagnosis rates, while the Ministry of Health and Prevention is expanding formularies and promoting generic substitution, which together translate into consistently rising procurement of anti-diabetic, cardiovascular, and metabolic drugs across public and private healthcare channels.
The UAE's structural differentiator is its role as a regional gateway for pharmaceutical trade, distribution, and medical tourism. Positioned between Asia, Europe, and Africa, the country serves as a distribution center for the Middle East, Africa, and South Asia through its ports and Dubai International Airport, and Jebel Ali Free Zone alone hosts over 160 healthcare and pharmaceutical firms from more than 38 countries. Medical tourism, supported by initiatives such as the Dubai Health Experience portal, attracts international patients for oncology, orthopedics, dermatology, and cardiology, encouraging hospitals to stock a wide range of branded and specialty products. The country's clinical trials ecosystem has also grown by 40% since 2020, strengthening its appeal for innovative therapies.
Government policy is accelerating the shift toward pharmaceutical self-sufficiency and faster market access. Through the National Strategy for the Pharmaceutical Industry, the Dubai Industrial Strategy 2030, and the Vision 2031 framework, the government offers tax exemptions, manufacturing grants, and fast-track licensing in free zones such as Dubai Science Park, Khalifa Industrial Zone Abu Dhabi, and Jebel Ali Free Zone. Federal Decree-Law No. 38 of 2024, enacted by the Emirates Drug Establishment in January 2025, established accelerated approval pathways for innovative drugs and biosimilars, while the Establishment has licensed 37 facilities for the production of human pharmaceutical and medical products. These measures are reducing import dependency and strengthening national drug security.
Government Schemes and UAE Vision 2031 Initiatives Driving Demand:
Emirates Drug Establishment and Federal Decree-Law No. 38 of 2024: Established in September 2023 as the sole federal authority regulating all medical and pharmaceutical products, the Emirates Drug Establishment (EDE) is implementing accelerated approval pathways for innovative drugs and biosimilars. Under this framework, the UAE became the second country in the world to authorize Lipfendra for high cholesterol in August 2026 and the second country globally to approve MIMRYLO (rusfertide) for polycythemia vera in September 2026.
Holistic National Manufacturing Project: Launched by the EDE at World Health Expo 2026 in February 2026, the project provides a national framework for localizing the production of advanced medicines and human medical products across the full value chain, from active ingredients and raw materials through manufacturing, packaging, storage, and distribution. To date, the EDE has licensed 37 facilities for the production of human pharmaceutical and medical products.
Abu Dhabi HELM Life Sciences Cluster: Launched in April 2025 and led by the Abu Dhabi Investment Office and the Department of Health Abu Dhabi, with support from MBZUAI, M42, and Hub71, the Health, Endurance, Longevity and Medicine cluster aims to build scalable infrastructure for AI-based drug discovery and precision medicine. It is projected to contribute AED 94 Billion to Abu Dhabi's economy and create 30,000 new jobs by 2045.
Make it in the Emirates and Pharmaceutical Localization: At Make it in the Emirates 2026 in May 2026, the EDE signed an MoU with Globalpharma to localize pharmaceutical manufacturing, accelerate domestic production projects, and attract technology transfer, while also holding discussions with MSD and Novo Nordisk on supply chain resilience and research and development. The initiative supports the UAE's broader industrial diversification agenda by strengthening the competitiveness of locally produced medicines.
National Essential Medicines List and Pharmacovigilance Reforms: In June 2025, the national regulator approved the UAE National Essential Medicines List through Resolution No. 47 of 2025, and in July 2026 it approved a Pharmacovigilance Practice guideline for medical products. These measures standardize priority medicine availability and post-market safety monitoring across federal and emirate-level healthcare systems.
UAE Pharmaceutical Market Industry Segmentation:
The report has segmented the market into the following categories:
Breakup By Type:
Pharmaceutical Drugs (Cardiovascular, Dermatology, Gastrointestinal, Genito-Urinary, Hematology, Anti-Infective, Metabolic Disorder, Musculoskeletal Disorder, Central Nervous System, Oncology, Ophthalmology, and Respiratory Diseases Drugs)
Biologics (Monoclonal Antibodies, Therapeutic Proteins, Vaccines)
Pharmaceutical drugs dominate with a market share of 71.6% in 2025, owing to their wide therapeutic application across chronic disease management, acute care, and preventive healthcare. Conventional synthetic drugs benefit from well-established clinical evidence, physician prescribing confidence, and mature manufacturing infrastructure, while government initiatives promoting generics as alternatives to branded drugs and the high prevalence of diabetes, hypertension, cardiovascular, and respiratory conditions keep these categories among the most widely prescribed in the country.
Breakup By Nature:
Organic
Conventional
Conventional leads with a share of 88.4% in 2025, driven by well-established clinical protocols, wider product availability, physician familiarity, and a lower cost structure compared with organic alternatives. Synthetic small molecules and generic medicines benefit from economies of scale in chemical synthesis, and regulators including the Ministry of Health and Prevention and the Emirates Drug Establishment have made it easier for healthcare agencies and insurers to procure conventional generics, supported by digital dispensing systems such as Dubai Health Authority's electronic prescription platforms.
Breakup By Region:
Dubai
Abu Dhabi
Sharjah
Others
Competitive Landscape:
The UAE pharmaceutical market has a competitive and varied landscape, including multinational companies, local manufacturers, and new local players. Some of the major companies operating in the market include:
Pfizer
Novartis
AstraZeneca
Bayer
Sanofi
Julphar
Neopharma
Pharmax Pharmaceuticals
Multinational companies maintain strong footholds through established distribution channels, broad product portfolios, and partnerships with healthcare institutions, while local manufacturers such as Julphar, Neopharma, and Pharmax Pharmaceuticals have expanded their manufacturing capabilities to serve both local and export markets. Key players are driving growth through portfolio expansion, strategic manufacturing partnerships, technology transfer, and investments in research and development, regulatory compliance, and technology integration.
What Does The Full Report Cover?
Historical market performance from 2020-2025 and forecasts for 2026-2034 in USD Billion
Detailed analysis by type, covering pharmaceutical drugs across 12 therapeutic categories and biologics including monoclonal antibodies, therapeutic proteins, and vaccines
Market breakup by nature, comparing organic and conventional pharmaceuticals
Regional assessment across Dubai, Abu Dhabi, Sharjah, and other emirates
Key trends, including digital health integration, local manufacturing expansion, and the rise of biologics, biosimilars, and precision medicine
Industry catalysts and challenges, including import reliance, regulatory compliance requirements, and skilled workforce shortages
Competitive landscape covering multinational and local pharmaceutical companies
Recent News and Developments in UAE Pharmaceutical Market
December 2025: IROS, an Abu Dhabi-based contract research organization and part of the M42 Group, partnered with BioSapien to conduct a six-month interventional oncology clinical trial in Abu Dhabi, starting in the first quarter of 2026, focused on lower gastrointestinal cancers using BioSapien's MediChip platform. The partnership highlights the growth of the UAE's clinical trials ecosystem, which has expanded by 40% since 2020.
May 2026: The Emirates Drug Establishment signed an MoU with Globalpharma, one of the UAE's leading local pharmaceutical manufacturers, at Make it in the Emirates 2026 to strengthen cooperation in localizing pharmaceutical manufacturing, accelerate domestic production projects, and attract technology transfer to the UAE.
July 2026: The Department of Health Abu Dhabi, AstraZeneca, and PureHealth signed an MoU at the BIO International Convention to activate a Rare Diseases Centre of Excellence in Abu Dhabi. The collaboration covers integrated diagnosis and lifelong care, patient access, clinical trials and real-world evidence generation, and capability building, leveraging infrastructure such as the Emirati Genome Program.
September 2026: The UAE became the second country globally to approve MIMRYLO (rusfertide) for adults with polycythemia vera, a chronic blood disorder, following its approval of Lipfendra for high cholesterol in August 2026, underscoring the Emirates Drug Establishment's accelerated pathways for innovative medicines.
October 2026: UAE-based manufacturer ADCAN Pharma signed five licensing and local manufacturing agreements and binding term sheets with international partners at CPHI Milan 2026, spanning cardiovascular disease, diabetes, and oncology. The deals are intended to support technology transfer and expand pharmaceutical production in the UAE, Saudi Arabia, and the wider Middle East.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
Key Questions This Report Answers
How big is the UAE pharmaceutical market, and what is its expected growth rate during 2026-2034?
What are the key factors driving pharmaceutical demand in the UAE?
How do pharmaceutical drugs and biologics compare in terms of market share and growth?
Which therapeutic categories generate the highest demand across the country?
How do Dubai, Abu Dhabi, Sharjah, and other emirates compare in market size?
How are local manufacturing initiatives and regulatory reforms reshaping the market?
Who are the key players, and what strategies are they adopting in the UAE pharmaceutical market?
About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Media and Sales Contact
IMARC Group
Email: sales@imarcgroup.com
United States: +1-201-971-6302
India: +91-120-433-0800
United Kingdom: +44-753-714-6104
Comments